monarchE: Subgroup Analysis of Abemaciclib + Adjuvant ET vs ET Alone in Patients With High-Risk HR+/HER2- Early Breast Cancer Who Received Prior Neoadjuvant Chemotherapy

In this prespecified subgroup analysis of patients with HR+/HER2- early breast cancer who received prior neoadjuvant chemotherapy, the subgroup showed a higher risk of recurrence vs the ITT population and had a numerically greater benefit for both invasive DFS and distant RFS with abemaciclib + adjuvant ET.